[0317 시황레이더] Samsung Biologics’ decision to invest in new plant 5 in Songdo’s 2nd Bio Campus rose slightly
[인포스탁데일리=박상철 기자]
K-Car (KS:), rising 9% due to stable improvement in profitability per unit and prospects for recovery in sales growth
As for Hyundai Motor Securities, sales and profit loss in 1Q23 fell short of expectations as K-Car continued its profitability-oriented business by reducing inventory and increasing turnover since the end of last year, but strategies to recover per-vehicle profits such as direct purchases, cost reduction, and e-commerce expansion are still in place. said it was working.
In addition, it forecasts that volume and ASP recovery will materialize through 3Q23 on the influence of used car interest rates that have stabilized since the second half of February. The stock price reflects the contraction in used car consumption in advance due to the interest rate hike, so it puts more weight on the possibility of an increase than a further decline. Following the stable improvement in profitability per unit and the recovery of sales growth, it is expected that the stock price will normalize with the effect of operating leverage.
▷ Investment opinion: BUY[유지]Target price: KRW 18,000[유지]
Nongshim (KS:) rose 3.5% due to expectations of achieving record-high operating profit this year
Shinhan Investment & Securities said that changes are being detected in consumption due to the recent economic downturn, and expectations for sales growth for ramen, which are relatively low in price, are high. In particular, the company’s average ASP, the No. 1 operator in the ramen market, is only KRW 667, and it has high price competitiveness compared to alternatives such as restaurants and convenience meals, even in terms of consumer prices.
Accordingly, despite two price hikes over the past two years, price competitiveness that is still high compared to substitutes and brand power built over a long period of time are expected to emerge as major strengths at present, when uncertainty is high.
In addition, he said that the cost burden is gradually easing as major grain prices have fallen since 2H09. Considering the lagging effect and the strong dollar, the cost burden was inevitable until 4Q22, but it has stabilized since 1Q23.
In particular, since wheat and palm oil, which had been burdensome for the company, have already returned to pre-surging levels, the company expects product price hikes and grain price declines to improve margin spreads from 2Q23. As a result, it is expected to achieve the highest operating profit this year.
▷ Investment recommendation: Buy[유지]Target price: KRW 390,000 -> KRW 450,000[상향]
Samsung Biologics (KS:) rose slightly due to the decision to invest in the 5th plant in the Songdo 2nd Bio Campus worth 1.98 trillion won
1.98 trillion won (22.01% of equity capital) announced the decision to invest in new facilities (new plant 5 in Songdo 2nd Bio Campus). The investment period is from March 17, 2023 to September 30, 2025, and the purpose of the investment is to strengthen competitiveness through expansion of biopharmaceutical production facilities, and it is planned to be built on a scale of 180,000L.
“The economic outlook for this year is still not good, but we will continue to grow steadily,” CEO John Lim said at the regular shareholders’ meeting. “Through the 2nd biocampus, we will build biopharmaceutical production facilities and next-generation drug technology fostering research facilities,” he said. I will respond,” he said.
Meanwhile, Seorin Bio, which has Samsung Biologics as its main customer, also emerged in the market.
Intops (KQ:), Samsung Electronics (KS:) soared 27% on news of preparations for mass production of wearable robots
According to some media, Intops is said to have completed preparations for mass production, such as conducting pilot tests for Samsung Electronics’ wearable robot production.
In this regard, an industry insider said, “Intops started preparing for the production of wearable robots for Samsung Electronics last year and finished preparations.” “We also conducted pilot tests, but the timing of the customer’s release or exact quantity has not been decided.” .
Following 2021 and last year, Intops plans to carry out consignment production of Bear Robotics’ serving robots this year as well. “It is true that the company is focusing on robots and is investing its capabilities, and we are talking to several companies,” he said.
HLB (KQ:) Group shares rose to the news of the announcement of the pharmacokinetic results of drugs such as Rivoceranib at the American Clinical Pharmacology Conference
HLB announced through the media that it would present the pharmacokinetic results of drug interactions, including the targeted anti-cancer drug Rivoceranib, in the form of a poster at the American Society of Clinical Pharmacology (ASCPT).
This study was conducted to evaluate the potential risk in terms of drug interaction (DDI) related to ‘CYP3A4’, a drug metabolizing enzyme that plays the most important role in the human liver, when taking Rivoceranib with other drugs. The individual results for the drugs will be described in the labeling and will become the standard for the dosing method when taking Rivoceranib with various drugs.
HLB group stocks such as HLB, HLB Pharmaceuticals, HLB Life Sciences, and HLB Global rose on the news.
[종목]: HLB, HLB Pharmaceutical, HLB Life Science, HLB Global
Kodako (KQ:) plunges 12% on management designation reasons
After the market close on the previous day, it announced the occurrence of the reason for designation of management issues due to the loss of continuing business before corporate tax expenses exceeding 50% of equity capital in the second business year out of the last three business years. As a result, the company’s stock trading, which had been suspended the previous day amid concerns over designation of management issues, was resumed today.
Reporter Park Sang-cheol [email protected]
